Evidence map›Paper›PMID 41648616›Full record

ArticlebioRxiv : the preprint server for biology2026

PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockade.

William M Yashar, Itallia V Pacentine, Akram Taherinasab, Thai Nguyen, Samantha Worme, Mitsuhiro Tsuchiya, Theresa Lusardi, Chelsea Hutchinson, Thomas L Fillmore, Camilo Posso and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

William M YasharDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.ORCID 0000-0002-8850-9850
Itallia V PacentineDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.
Akram TaherinasabDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.
Thai NguyenDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.
Samantha WormeDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.
Mitsuhiro TsuchiyaDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.
Theresa LusardiKnight Cancer Institute, Oregon Health & Science University; Portland, OR, 97239, USA.
Chelsea HutchinsonBiological Sciences Division, Pacific Northwest National Laboratory, Richland WA.
Thomas L FillmoreEnvironmental and Molecular Sciences Division, Pacific Northwest National Laboratory, Richland WA.
Camilo PossoBiological Sciences Division, Pacific Northwest National Laboratory, Richland WA.
Sara Jc GoslineBiological Sciences Division, Pacific Northwest National Laboratory, Richland WA.
Paul D PiehowskiEnvironmental and Molecular Sciences Division, Pacific Northwest National Laboratory, Richland WA.
Galip Gurkan YardimciKnight Cancer Institute, Oregon Health & Science University; Portland, OR, 97239, USA.
Andrew C AdeyKnight Cancer Institute, Oregon Health & Science University; Portland, OR, 97239, USA.
Julia E MaxsonDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.ORCID 0000-0002-3871-7221
Theodore P BraunDivision of Oncologic Sciences, Department of Medicine, Oregon Health & Science University; Portland, OR, 97239, USA.ORCID 0000-0002-6248-2143

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Mechanisms of differentiation blockade in CSF3R-mutant AMLR01CA247943 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MAXSON, JULIA E · 2021 to 2025
$2.0M
Dual Kinase and LSD1 Inhibition in Acute Myeloid LeukemiaR01CA282133 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Theodore Paul Braun · 2023 to 2026
$2.0M
Epigenetics of Mutation-Order in Acute Myeloid LeukemiaK08CA245224 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BRAUN, THEODORE PAUL · 2020 to 2024
$812k
Control of the MYC Super-Enhancer Complex in FLT3-ITD Acute Myeloid LeukemiaF30CA278500 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI YASHAR, WILLIAM MONTGOMERY · 2024 to 2024
$32k
NCI NIH HHS F30 CA278500NCI NIH HHS K08 CA245224NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA247943NCI NIH HHS R01 CA282133
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) exhibits substantial transcriptional heterogeneity across differentiation states that influences therapeutic response to BCL2 inhibition with venetoclax. While hematopoietic stem cell (HSC)-like AMLs show high sensitivity to venetoclax and monocytic-like AMLs demonstrate resistance, the therapeutic behavior of leukemias harboring both transcriptional programs remains poorly defined. Analysis of a large AML cohort reveals a distinct patient population exhibiting concurrent HSC- and monocyte-like transcriptional signatures, which we term stem-monocytic AML.

Indexed as

BCL2 inhibitionmyeloid differentiationPU.1stem-monocytic acute myeloid leukemiaVenetoclax

Identifiers

PMID41648616
PMCPMC12871714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.